Effects of Pioglitazone Add-On to Gliclazide and Metformin on Glycemic Control in Patients with Type 2 Diabetes

Objectives. This study aims to evaluate the efficacy and safety of adding pioglitazone to treatment with metformin (MF) and gliclazide in patients with type 2 diabetes mellitus (DM2) who had inadequate glycemic control. Methods. This study is a retrospective cohort study based on King Abdullah Unive...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine research 2012-02, Vol.37 (1), p.7-11
Main Authors: Al-Azzam, Sayer I., AlOmari, Mousa, Khader, Yousef S., AlMahasneh, Fatimah A., Muflih, Suhaib M., Altawalbeh, Shoroq
Format: Article
Language:English
Subjects:
Adult
Aged
Blood Glucose - drug effects
Blood Glucose - metabolism
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Drug Therapy, Combination
Female
Gliclazide
Gliclazide - pharmacology
Gliclazide - therapeutic use
Humans
Hypoglycemic Agents - pharmacology
Hypoglycemic Agents - therapeutic use
Male
Metformin
Metformin - pharmacology
Metformin - therapeutic use
Middle Aged
Pioglitazone
Retrospective Studies
Thiazolidinediones - pharmacology
Thiazolidinediones - therapeutic use
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives. This study aims to evaluate the efficacy and safety of adding pioglitazone to treatment with metformin (MF) and gliclazide in patients with type 2 diabetes mellitus (DM2) who had inadequate glycemic control. Methods. This study is a retrospective cohort study based on King Abdullah University Hospital records concerning type 2 diabetic adult patients for year 2008. Patients included were assessed according to changes in glycosylated hemoglobin (HbA1c), lipid profile, albuminuria and liver enzymes before and after the addition of pioglitazone. Results. The patients included in the study had an initial mean HbA1c of 9.44%, which decreased to 7.56% after the addition of pioglitazone (P-value < 0.005).
ISSN:0743-5800
1532-4206
DOI:10.3109/07435800.2011.566238